EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation

Lu Hao, Jiao Lu, Jisu Xue

Oncology Research · 2026 · 34 (5) · 1-10

DOI: 10.32604/or.2026.076420 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Lu Hao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Education, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo Chimeric Antigen Receptor (CAR)-T cell therapy reprograms a patient's own T cells directly inside the body, bypassing the complex and costly traditional manufacturing process. This is achieved by systemically delivering viral or non-viral vectors that genetically modify endogenous T lymphocytes to produce functional CAR-T cells de novo. By eliminating ex vivo cell processing, this strategy can simplify workflows, reduce costs, improve accessibility, and allow faster treatment. Key delivery platforms include engineered lentiviral and adeno-associated viral (AAV) vectors for lasting CAR expression and targeted lipid nanoparticles (LNPs) for transient mRNA delivery. Emerging technologies like biomaterial scaffolds and ultrasound stimulation further enable localized and spatiotemporally controlled T cell engineering. Clinically, early trials in relapsed/refractory multiple myeloma and B-cell malignancies have shown strong antitumor responses, even without preconditioning chemotherapy. Remaining challenges comprise achieving precise T cell targeting, overcoming the immunosuppressive tumor microenvironment, preventing antigen escape, and managing safety risks such as vector genotoxicity or LNP reactogenicity. Future translation will depend on combining synergistic regimens, refining vector design, and implementing tunable safety controls. The aim of the study is to highlight how in vivo CAR-T therapy is evolving from concept to clinical reality, poised to redefine adoptive cell therapy as a scalable and widely applicable pharmacologic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsT-LymphocytesHumansAnimalsGenetic VectorsGenetic TherapyTranslational Research, Biomedical

Stichwörter der Autor:innen

Chimeric antigen receptor-Tcancer treatmentcell therapygene therapyin vivo chimeric antigen receptor-T

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Science and Education, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China.
  • Department of Endocrinology, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China.

Zitieren

APA

Hao, L., Lu, J., & Xue, J. (2026). In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation. Oncology Research, 34(5), 1-10. https://doi.org/10.32604/or.2026.076420

Vancouver

Hao L, Lu J, Xue J. In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation. Oncology Research. 2026;34(5):1-10. doi:10.32604/or.2026.076420

BibTeX
@article{Hao2026,
  author = {Hao, Lu and Lu, Jiao and Xue, Jisu},
  title = {In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation},
  journal = {Oncology Research},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {1--10},
  doi = {10.32604/or.2026.076420}
}
Kostenlos starten →